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I N V I T E D  E D I T O R I A L
Editorial: evolution of GLP- 1 receptor agonists as 
pharmacotherapy for NASH beyond diabetes mellitus and 
obesity – authors’ reply
We thank Professor Kim for his editorial in response to our recent 
study1,2 of the imaging response associated with semaglutide treat-
ment in patients with NAFLD. We agree that larger and longer- term 
studies are needed to further assess the effect of semaglutide on 
long- term clinical outcomes in NASH. A phase III trial is underway to 
examine the role of semaglutide in improving the risk of progression 
to cirrhosis and long- term clinical outcomes (NCT04822181). This 
trial is global in outlook and will recruit patients from several Asian 
as well as Western countries.
Also, as noted in the editorial, it remains unclear to what extent 
the anti- steatotic efficacy of semaglutide is a direct effect or an indi-
rect effect mediated by weight loss. In addition to weight reduction, 
semaglutide is associated with improvements in insulin resistance, 
lipid dysfunction, and hepatic inflammation. In pre- clinical models, 
improvements in hepatic lipotoxicity and inflammation with the GLP- 1 
receptor agonist liraglutide were shown to be independent of weight 
reduction, as was the prevention of initiation of fibrosis.3 Mediation 
analyses to investigate the extent to which the effects of semaglutide 
on liver steatosis are mediated by weight reduction are planned.
The authors' declarations of personal and financial interests are 
unchanged from those in the original article.2
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